| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 77, 1046-1053, Copyright © 1993 by Endocrine Society
ARTICLES |
P Garnero and PD Delmas
INSERM Unit 234, Hopital E. Herriot, Lyon, France.
We measured serum bone alkaline phosphatase (B-ALP) with a new immunoradiometric assay (IRMA) in a large sample of healthy controls comprising 173 women and 180 men, 20-88 yr of age, and in patients with metabolic bone disease. Using serum samples from patients with liver disease and patients with Paget's disease with elevated total alkaline phosphatase (T-ALP) as a source of, respectively, liver and bone isoenzymes, we determined a liver cross-reactivity of the IRMA of 16% that was confirmed by electrophoresis of the circulating alkaline phosphatase isoenzymes. The IRMA was linear for serial sample dilutions, the recovery ranged from 89-110%, and the intra- and interassay variations were below 7% and 9%, respectively. B-ALP increased linearly with age in both sexes, and the mean B-ALP serum levels were not significantly different for women and men (11.3 +/- 4.8 ng/mL for women; 11.0 +/- 4.0 ng/mL for men). The increase in B-ALP after the menopause was significantly higher than that in T-ALP (+77% vs. +24%; P < 0.001). When the values of postmenopausal women were expressed as the SD from the mean of premenopausal women, the mean Z scores were 2.2 +/- 1.8 for B-ALP and 0.9 +/- 1.3 for T-ALP (P < 0.001 between the two). Serum B-ALP was increased from control values in patients with Paget's disease (n = 57; mean, 171.8 +/- 135.6 ng/mL; P < 0.001), in patients with primary hyperparathyroidism (n = 18; mean, 17.2 +/- 5.9 ng/mL; P < 0.001), and in patients with chronic renal failure on hemodialysis (n = 83; mean, 36.6 +/- 35.7 ng/mL; P < 0.001). In patients with Paget's disease, B-ALP was highly correlated with T- ALP (r2 = 0.94; P < 0.001), and the decrease in its serum level was larger than that in T-ALP after treatment with the bisphosphonate pamidronate (-58% vs. -43%; P < 0.03). In patients with various liver diseases, B-ALP was slightly increased, but stayed within the normal range (mean +/- 2 SD) until T-ALP did not exceed 4.5 mu katal/L. We conclude that this new IRMA for B-ALP is reliable, has a low cross- reactivity with the liver isoenzyme, and appears to be more sensitive than T-ALP for the clinical investigation of patients with osteoporosis and other metabolic bone diseases.
This article has been cited by other articles:
 |
|
 |
|
  P. Garnero, P. Vergnaud, and N. Hoyle Evaluation of a Fully Automated Serum Assay for Total N-Terminal Propeptide of Type I Collagen in Postmenopausal Osteoporosis Clin. Chem., January 1, 2008; 54(1): 188 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Maimoun, D Simar, D Malatesta, C Caillaud, E Peruchon, I Couret, M Rossi, and D Mariano-Goulart Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects Br. J. Sports Med., August 1, 2005; 39(8): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Greenspan, N. M. Resnick, and R. A. Parker Early Changes in Biochemical Markers of Bone Turnover Are Associated with Long-Term Changes in Bone Mineral Density in Elderly Women on Alendronate, Hormone Replacement Therapy, or Combination Therapy: A Three-Year, Double-Blind, Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2762 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Stone, D. C. Bauer, D. Sellmeyer, and S. R. Cummings Low Serum Vitamin B-12 Levels Are Associated with Increased Hip Bone Loss in Older Women: A Prospective Study J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1217 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Aris, G. E. Lester, M. Caminiti, A. D. Blackwood, M. Hensler, R. K. Lark, T. M. Hecker, J. B. Renner, U. Guillen, S. A. Brown, et al. Efficacy of Alendronate in Adults with Cystic Fibrosis with Low Bone Density Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 77 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Arjmandi, D. A. Khalil, B. J. Smith, E. A. Lucas, S. Juma, M. E. Payton, and R. A. Wild Soy Protein Has a Greater Effect on Bone in Postmenopausal Women Not on Hormone Replacement Therapy, as Evidenced by Reducing Bone Resorption and Urinary Calcium Excretion J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1048 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Khalil, E. A. Lucas, S. Juma, B. J. Smith, M. E. Payton, and B. H. Arjmandi Soy Protein Supplementation Increases Serum Insulin-Like Growth Factor-I in Young and Old Men but Does Not Affect Markers of Bone Metabolism J. Nutr., September 1, 2002; 132(9): 2605 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Chapurlat, S. K. Ewing, D. C. Bauer, and S. R. Cummings Influence of Smoking on the Antiosteoporotic Efficacy of Raloxifene J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4178 - 4182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Woitge, E. Horn, A. V. Keck, B. Auler, M. J. Seibel, and M. Pecherstorfer Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis Clin. Chem., April 1, 2001; 47(4): 686 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Alexandersen, B. J. Riis, J. A. Stakkestad, P. D. Delmas, and C. Christiansen Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 755 - 760. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. ARIS, G. E. LESTER, J. B. RENNER, A. WINDERS, A. DENENE BLACKWOOD, R. K. LARK, and D. A. ONTJES Efficacy of Pamidronate for Osteoporosis in Patients with Cystic Fibrosis following Lung Transplantation Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 941 - 946. [Abstract] [Full Text]
|
|
|
|
|
|
A. Caillot-Augusseau, L. Vico, M. Heer, D. Voroviev, J.-C. Souberbielle, A. Zitterman, C. Alexandre, and M.-H. Lafage-Proust Space Flight Is Associated with Rapid Decreases of Undercarboxylated Osteocalcin and Increases of Markers of Bone Resorption without Changes in Their Circadian Variation: Observations in Two Cosmonauts Clin. Chem., August 1, 2000; 46(8): 1136 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Woitge, H. Oberwittler, S. Heichel, A. Grauer, R. Ziegler, and M. J. Seibel Short- and Long-Term Effects of Ibandronate Treatment on Bone Turnover in Paget Disease of Bone Clin. Chem., May 1, 2000; 46(5): 684 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Garnero, Y. Tsouderos, I. Marton, C. Pelissier, C. Varin, and P. D. Delmas Effects of Intranasal 17{beta}-Estradiol on Bone Turnover and Serum Insulin-Like Growth Factor I in Postmenopausal Women J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2390 - 2397. [Abstract] [Full Text]
|
|
|
|
|
|
B. C. Kress, I. A. Mizrahi, K. W. Armour, R. Marcus, R. D. Emkey, and A. C. Santora II Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women Clin. Chem., July 1, 1999; 45(7): 1009 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Broyles, R. G. Nielsen, E. M. Bussett, W. D. Lu, I. A. Mizrahi, P. A. Nunnelly, T. A. Ngo, J. Noell, R. H. Christenson, and B. C. Kress Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase Clin. Chem., October 1, 1998; 44(10): 2139 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Saag, R. Emkey, T. J. Schnitzer, J. P. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, U. A. Liberman, P. D. Delmas, M.-P. Malice, et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis N. Engl. J. Med., July 30, 1998; 339(5): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pearce, D. A. Tabensky, P. D. Delmas, H. W. G. Baker, and E. Seeman Corticosteroid-Induced Bone Loss in Men J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 801 - 806. [Abstract] [Full Text]
|
|
|
|
|
|
A. Caillot-Augusseau, M.-H. Lafage-Proust, C. Soler, J. Pernod, F. Dubois, and C. Alexandre Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95) Clin. Chem., March 1, 1998; 44(3): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Delmas, N. H. Bjarnason, B. H. Mitlak, A.-C. Ravoux, A. S. Shah, W. J. Huster, M. Draper, and C. Christiansen Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women N. Engl. J. Med., December 4, 1997; 337(23): 1641 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Price, T. P. Milligan, and C. Darte Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum Clin. Chem., November 1, 1997; 43(11): 2052 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Osella, M. Terzolo, G. Reimondo, A. Piovesan, A. Pia, A. Termine, P. Paccotti, and A. Angeli Serum Markers of Bone and Collagen Turnover in Patients with Cushing's Syndrome and in Subjects with Adrenal Incidentalomas J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3303 - 3307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bauer, M. C. Nevitt, B. Ettinger, and K. Stone Low Thyrotropin Levels Are Not Associated with Bone Loss in Older Women: A Prospective Study J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2931 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Withold, H. W. Woitge, and M. J. Seibel More on Total and Bone-Specific Alkaline Phosphatase • Authors of the article referred to respond: Clin. Chem., September 1, 1997; 43(9): 1670 - 1671. [Full Text]
|
|
|
|
|
|
H. Tobiume, S. Kanzaki, S. Hida, T. Ono, T. Moriwake, S. Yamauchi, H. Tanaka, and Y. Seino Serum Bone Alkaline Phosphatase Isoenzyme Levels in Normal Children and Children with Growth Hormone (GH) Deficiency: A Potential Marker for Bone Formation and Response to GH Therapy J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2056 - 2061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vergnaud, P. Garnero, P. J. Meunier, G. Breart, K. Kamihagi, and P. D. Delmas Undercarboxylated Osteocalcin Measured with a Specific Immunoassay Predicts Hip Fracture in Elderly Women: The EPIDOS Study J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 719 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Withold, F. P. Armbruster, M. Karmatschek, and H. Reinauer Bone sialoprotein in serum of patients with malignant bone diseases Clin. Chem., January 1, 1997; 43(1): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H.-J. Hsu and K.-S. Tsai Different Age-Related Trends of Bone and Nonbone Forms of Alkaline Phosphatase in Chinese Men and Women Clin. Chem., January 1, 1997; 43(1): 186 - 188. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
